Boston Scientific analyst views diverge, shares under S&P 500 scrutiny

Boston Scientific draws mixed analyst commentary, with TD Cowen and Piper Sandler reiterating positive ratings while the S&P 500 constituent trades below its recent highs.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 12:09.

Boston Scientific (US10117L1017) sits in the S&P 500 with a valuation shaped increasingly by analyst commentary. Recent notes from TD Cowen and Piper Sandler outline differing emphases on the medtech group's earnings trajectory and recovery expectations according to market reports. TD Cowen update on Boston Scientific

What TD Cowen highlights

TD Cowen analyst Josh Jennings reiterates a Buy recommendation on Boston Scientific with a price target of 61 US dollars, pointing to potential upside from the current share price level. Analyst note summarizing Jennings' view The report mentions that Boston Scientific shares have declined more than 50 percent year to date, with consensus expecting a recovery of more than 60 percent from recent prices. Yahoo Finance BSX analysis page

Jennings underlines that management still guides for achieving at least the lower end of its revenue and earnings per share objectives for the second quarter of 2026. He notes that expectations have been adjusted downward in recent weeks, which he views as making the EPS targets more attainable. BSX key statistics overview

Piper Sandler and other estimates

Piper Sandler maintains an Overweight rating on Boston Scientific, according to recent consensus compilations, and continues to forecast organic growth in line with management's long-term target range. MarketBeat analyst estimates for BSX Estimate tables show that most covering houses now cluster around mid-single-digit earnings growth for fiscal 2026.

Aggregated data from MarketBeat and other services indicate that a majority of analysts rate Boston Scientific shares as Buy or equivalent, while a smaller group sits at Hold. MarketBeat earnings summary for BSX The consensus earnings per share estimate for 2026 stands modestly above the 2025 outcome, consistent with a cautiously positive stance on the medtech sector.

The products behind the group

Boston Scientific generates most of its revenue from minimally invasive medical devices in cardiology, rhythm management and endoscopy. A flagship product family is the Watchman left atrial appendage closure system, used to reduce stroke risk in patients with atrial fibrillation who are not suitable for long-term anticoagulation therapy. Company page on the Watchman LAAC system

Where the shares trade today

Boston Scientific shares (US10117L1017) last closed on the NYSE at 44.20 US dollars on 2026-06-25, with after-hours indications near 44.15 US dollars according to exchange data.

Key data on the Boston Scientific shares

• Company: Boston Scientific Corporation
• ISIN: US10117L1017
• WKN: 879189
• Ticker: BSX
• Trading venue: NYSE
• Price (as of 2026-06-25, 15:59): 44.20 USD
• Market cap: approximately 64 billion USD (as of 2026-06-25)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article provides factual information on the Boston Scientific shares and does not contain investment advice or personal recommendations. Investors should base decisions on their own research and, where appropriate, seek professional counsel.